A phase I study was conducted on 10 recurrent GBM patients with four days of mTOR inhibitor ridaforolimus administered daily at an intravenous dose of 12.5 to 15 mg prior to re-resection and continued postoperatively [83]. The gene discussed is MTOR; the disease is glioblastoma.